Medscape is available in 5 Language Editions – Choose your Edition here.


Pachyonychia Congenita Clinical Presentation

  • Author: Saira J George, MD; Chief Editor: William D James, MD  more...
Updated: Mar 30, 2016


Thickened toenails, plantar keratoderma, and plantar pain are the 3 cardinal findings of pachyonychia congenita (seen in >90% of patients) and are present in most patients before age 5 years.[5, 6] Clinical differences among pachyonychia congenita subtypes include earlier onset and more frequent occurrence of nail dystrophy and keratoderma in pachyonychia congenita type K6a, concurrent fingernail and toenail thickening in pachyonychia congenita types K6a and K17, more palmar keratoderma in pachyonychia congenita type K16, more frequent occurrence of cysts in pachyonychia congenita type K17, follicular hyperkeratoses primarily in pachyonychia congenita type K6a, oral leukokeratoses most often in pachyonychia congenita type K6a, and natal teeth almost exclusively in pachyonychia congenita K17.[5, 6]

Thickened toenails

The development of thickened toenails in childhood is seen in almost all patients with pachyonychia congenita.[12, 5] The thickened nails often require constant paring and grooming to prevent overgrowth and trauma, and they may be accompanied by painful paronychia (both pressure related and infectious). In a large study, 249 of 254 (98%) patients reported toenail changes, involving an average number of 8.8 toenails (range 0-10, mode = 10). Patients with KRT6A mutations were 11.1 times as likely to have all 10 toenails affected than those with the KRT6B, KRT16, or KRT17 mutations. The characteristic thickened toenails typically develop early in life. This appears to be especially true for patients with KRT6A mutations whose age of onset averaged 0.35 years (or 4 mo) compared with those with KRT6B, KRT16, or KRT17 mutations (9.5 y, 6.8 y, and 0.9 y, respectively).


Plantar keratoderma is the next most common finding of the disorder and occurs in 91-96% of patients.[12, 5] It typically develops in early childhood with the start of prolonged walking and weight bearing. It most commonly manifests as persistent large callouses on weight-bearing surfaces and may be preceded or accompanied by blistering. Fissuring and secondary infection may also occur. Palmar keratoderma is also often present, especially among patients with KRT16 mutations.

Plantar pain

The third most commonly encountered finding among patients with pachyonychia congenita is pain, mostly involving weight-bearing areas such as the plantar surfaces. In a large study, 89% of patients (225 of 254) reported pain.[5] Of note, plantar pain appears to be the most important feature to negatively impact quality of life among people with pachyonychia congenita and may be severe enough to result in limitation of activities or require medications to manage it. 

Fingernail dystrophy

Fingernail dystrophy is also a feature of pachyonychia congenita, although slightly less consistently than toenail dystrophy. Thickened fingernails were reported in 220 of 254 (87%) patients in a large study.[5] The prevalence of fingernail changes appears to be highest in patients with KRT6A mutation. All of the 115 patients with KRT6A mutations and 40 (93%) of 43 with KRT17 mutations reported fingernail changes, whereas 56 (74%) of 76 with KRT16 and only 9 (45%) of 20 with KRT6B mutation carriers reporting affected fingernails. KRT6B mutation carriers were also found to have far fewer fingernails affected than the other mutations carriers.

Mucosal findings

Oral leukokeratotic plaques (which are not felt to be premalignant) are estimated to occur in approximately 70% of patients with pachyonychia congenita.[5, 12] They may be seen at birth or develop within the first year. The plaques are most commonly seen on the tongue and buccal surfaces of the mouth. In newborns, the leukokeratoses may lead to difficulties in suckling and breastfeeding. In a large study, 97% (115/115) KRT6A and 59% (45/76) KRT16 mutation carriers reported the finding compared with 7/20 (35%) KRT6B and 14/43 (33%) KRT17 mutation carriers.


Historically, the presence of various pilosebaceous cysts, such as steatocystomas or vellus hair cysts, were thought to be a reliable distinguishing feature of pachyonychia congenita type II.[12, 13, 14, 15] In a large study, cysts of any type were reported in 104 of 254 (41%) patients. Cysts were reported in 38 of 43 (88%) patients with KRT17 mutation, in 11 of 20 (55%) KRT6B mutation carriers, in 47 of 115 (41%) KRT6A mutation carriers, and 8 of 76 (11%) KRT16 mutation carriers.[5]

Natal teeth

Natal or prenatal teeth are associated with pachyonychia congenita and present at birth or within the first 30 days of life.[12, 13, 16] They are typically lost in infancy and replaced with normal permanent teeth during childhood. Natal teeth may lead to trauma or lacerations of the infant’s tongue or mother’s breast during breastfeeding and can pose an aspiration risk in infancy They were previously reported to be a feature of pachyonychia congenita type 2. In a large study, 39 of the 254 patients reported natal teeth. Thirty six were KRT17 mutation carriers. Only 3 of 115 (3%) KRT6A carriers reported natal teeth, and none of the 96 patients with KRT16 or KRT6B mutation carriers reported natal teeth.[5]



Nail dystrophy

Nail involvement usually demonstrates significant subungual hyperkeratosis and sometimes presents with premature termination of nail. The nails may grow to full length and have an upward-slanted or heaped-up appearance due to a progressive distal thickening, or the plate may terminate prematurely with a gently sloped distal edge of hyperkeratosis and exposed distal finger tip. The surface of the plate can be smooth or rough and is often discolored. Note the image below.

The most prominent feature is a substantially thic The most prominent feature is a substantially thickened, brownish gray nail plate with a rough surface.

Plantar keratoderma

The plantar keratoderma of pachyonychia congenita is typically symmetric and focal, developing in areas of friction, trauma, and weight bearing , although it may affect the entire plantar surface. Blisters, fissures, and open sores often develop within or adjacent to the calloused areas.

Follicular hyperkeratoses reminiscent of severe keratosis pilaris have been reported and are most frequently found on the elbows and knees and along the waistband area. Note the image below.

Hyperkeratotic lesions of the skin may involve aca Hyperkeratotic lesions of the skin may involve acanthosis, hyperkeratosis, and parakeratosis.

Oral leukokeratosis

Leukokeratosis of the oral mucosa, as shown below, is seen as patchy whitish areas most commonly seen on the tongue and buccal mucosa. The gingival mucosa is rarely involved. The clinical appearance of the lingual and buccal leukokeratosis can resemble candidiasis and premalignant leukoplakia, respectively. Buccal lesions are often accentuated at areas of trauma such as along the bite line.

Leukokeratosis of the oral mucosa is a prominent s Leukokeratosis of the oral mucosa is a prominent sign. Patchy whitish areas may be seen on the back of the tongue; the buccal mucosa; and sometimes, the gingiva.

Natal teeth

Natal or prenatal teeth can generally be seen in a frontal position and are often friable and prone to caries.

Pilosebaceous cysts

Although various pilosebaceous cysts have been reported in pachyonychia congenita, steatocystomas and vellus hair cysts have been historically most associated. Steatocystomas present as numerous small skin-colored to yellow-colored cysts that range from a few millimeters to a few centimeters and typically occur in sebaceous gland–dense areas such as the chest, arms, armpit, and neck.

Contributor Information and Disclosures

Saira J George, MD Assistant Professor of Dermatology, The University of Texas MD Anderson Cancer Center

Saira J George, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Lester F Libow, MD Dermatopathologist, South Texas Dermatopathology Laboratory

Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Gregory J Raugi, MD, PhD Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle School of Medicine; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle

Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Aleksej Kansky, MD, PhD, to the development and writing of this article.

  1. Muller C. On the causes of congenital onychogryphosis. Mcn Med Wochenschr. 1904. 49:2180-2.

  2. Wilson AG. Three cases of hereditary hyperkeratosis of the nail bed. Br J Dermatol. 1905. 17:13-14.

  3. Jadassohn J, Lewandowsky F. Pachyonychia congenita. Keratosis disseminata circumscripta (follicularis). Tylomata. Leukokeratosis linguae. Jacob's Ikonographia Dermatologica. Berlin: Urban und Schwarzenberg; 1906. 1: 29-30.

  4. McKusick V. Mendelian Inheritance in Man. 11th ed. Baltimore: J Hopkins University Press; 1994.

  5. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol. 2012 Jan 18. [Medline].

  6. Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol. 2014 Feb 1. 150(2):146-53. [Medline].

  7. Liao H, Sayers JM, Wilson NJ, Irvine AD, Mellerio JE, Baselga E. A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci. 2007 Dec. 48(3):199-205. [Medline].

  8. Terrinoni A, Smith FJ, Didona B, et al. Novel and recurrent mutations in the genes encoding keratins K6a, K16 and K17 in 13 cases of pachyonychia congenita. J Invest Dermatol. 2001 Dec. 117(6):1391-6. [Medline].

  9. Smith FJ, Liao H, Cassidy AJ, et al. The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):21-30. [Medline].

  10. Kaspar RL. Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):62-6. [Medline].

  11. Smith FJD, Kaspar RL, Schwartz ME, McLean WHI, Leachman SA. Pachyonychia Congenita. 1993. [Medline].

  12. Leachman SA, Kaspar RL, Fleckman P, et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):3-17. [Medline].

  13. Feinstein A, Friedman J, Schewach-Millet M. Pachyonychia congenita. J Am Acad Dermatol. 1988 Oct. 19(4):705-11. [Medline].

  14. Munro CS. Pachyonychia congenita: mutations and clinical presentations. Br J Dermatol. 2001 May. 144(5):929-30. [Medline].

  15. Moon SE, Lee YS, Youn JI. Eruptive vellus hair cyst and steatocystoma multiplex in a patient with pachyonychia congenita. J Am Acad Dermatol. 1994 Feb. 30(2 Pt 1):275-6. [Medline].

  16. Clementi M, Cardin de Stefani E, Dei Rossi C, Avventi V, Tenconi R. Pachyonychia congenita Jackson-Lawler type: a distinct malformation syndrome. Br J Dermatol. 1986 Mar. 114(3):367-70. [Medline].

  17. Su WP, Chun SI, Hammond DE, Gordon H. Pachyonychia congenita: a clinical study of 12 cases and review of the literature. Pediatr Dermatol. 1990 Mar. 7(1):33-8. [Medline].

  18. Wollina U, Schaarschmidt H, Fünfstück V, Knopf B. Pachyonychia congenita. Immunohistologic findings. Zentralbl Pathol. 1991. 137(4):372-5. [Medline].

  19. Milstone LM, Fleckman P, Leachman SA, et al. Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):18-20. [Medline].

  20. Tidman MJ, Wells RS. Control of plantar blisters in pachyonychia congenita with topical aluminium chloride. Br J Dermatol. 1988 Mar. 118(3):451-2. [Medline].

  21. Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006 Apr. 154(4):763-5. [Medline].

  22. González-Ramos J, Sendagorta-Cudós E, González-López G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016 Jan. 29 (1):32-6. [Medline].

  23. Thomas DR, Jorizzo JL, Brysk MM, Tschen JA, Miller J, Tschen EH. Pachyonychia congenita. Electron microscopic and epidermal glycoprotein assessment before and during isotretinoin treatment. Arch Dermatol. 1984 Nov. 120(11):1475-9. [Medline].

  24. Dupre A, Christol B, Bonafe JL, Touron P. [Pachyonychia congenita. Three familial cases. Effects of the treatment by aromatic retinoid (RO 10.9359) (author's transl)]. Ann Dermatol Venereol. 1981. 108(2):145-9. [Medline].

  25. Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci. 2009 Nov. 56(2):82-8. [Medline].

  26. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb. 18(2):442-6. [Medline]. [Full Text].

  27. Trochet D, Prudhon B, Vassilopoulos S, Bitoun M. Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls. Curr Gene Ther. 2015. 15 (5):503-10. [Medline].

  28. U.S. Food and Drug Administration (FDA). Orphan Drug Designations and Approvals. Sirolimus; treatment of pachyonychia congenita. Available at Accessed: January 24, 2014.

  29. Wallis T, Poole CD, Hoggart B. Can skin disease cause neuropathic pain? A study in pachyonychia congenita. Clin Exp Dermatol. 2016 Jan. 41(1):26-33. [Medline].

  30. Thomsen RJ, Zuehlke RL, Beckman BI. Pachyonychia congenita: surgical management of the nail changes. J Dermatol Surg Oncol. 1982 Jan. 8(1):24-8. [Medline].

  31. GARB J. Pachyonychia congenita; regression of plantar lesions on patients wearing specially made rubber base foot molds and shoes. Arch Derm Syphilol. 1950 Jul. 62(1):117-24. [Medline].

The most prominent feature is a substantially thickened, brownish gray nail plate with a rough surface.
Leukokeratosis of the oral mucosa is a prominent sign. Patchy whitish areas may be seen on the back of the tongue; the buccal mucosa; and sometimes, the gingiva.
Hyperkeratotic lesions of the skin may involve acanthosis, hyperkeratosis, and parakeratosis.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.